查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933381

全球胃腸道治療市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Gastrointestinal Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 225 Pages | 商品交期: 請詢問到貨日

價格

胃腸道（GI）治療市場成長因子

受胃腸道疾病盛行率和認知度不斷提高以及藥物研發持續創新的推動，全球胃腸道（GI）治療市場正經歷穩定成長。胃腸道治療藥物包括用於治療胃食道逆流（GERD）、發炎性腸道疾病（IBD）、腸躁症（IBS）、胃腸道癌症和其他功能性消化系統疾病的藥物。根據 Fortune Business Insights 預測，到 2025 年，全球胃腸道治療市場規模將達到 806 億美元，凸顯了全球對有效消化系統健康治療的巨大需求。

市場規模及預測

預計到2026年，全球胃腸道疾病治療市場規模將增長至891.1億美元，主要驅動因素包括診斷率的提高、抑酸治療需求的強勁增長以及生物製劑在慢性胃腸道疾病治療中的應用日益廣泛。長期來看，預計該市場在預測期內將以5.09%的複合年增長率成長，到2034年達到1,409.8億美元。

截至2025年，北美地區以42.32%的市佔率引領全球胃腸道疾病治療市場。這主要得益於該地區較高的疾病盛行率、完善的醫療保健基礎設施以及先進療法的早期應用。

市場驅動因素

推動市場成長的關鍵因素之一是全球胃腸道疾病盛行率的不斷上升。 生活方式的改變，例如不健康的飲食、缺乏運動、飲酒量增加和壓力，顯著加劇了胃腸道疾病的負擔。不斷擴大的患者群體推動了對有效治療方案和先進診斷技術的需求。

據克羅恩病和結腸炎基金會統計，截至2023年6月，美國將有160萬至310萬人患有發炎性腸道疾病，凸顯了長期疾病管理和促進藥物創新的必要性。

市場限制因子

儘管市場穩定成長，但由於先進療法（尤其是生物製劑和標靶療法）的高昂成本，市場仍面臨許多限制因素。這些療法需要大量的研發投入，而且價格昂貴，難以取得，尤其是在中低收入國家。 有限的保險覆蓋範圍進一步加重了病患的經濟負擔。

例如，據報道，在美國，5 mg/kg劑量的英夫利西單抗的總費用約為2,634美元，這限制了先進療法的成本效益，並減緩了其廣泛應用。

市場機會

對生物製劑和標靶療法的日益關注帶來了巨大的成長機會。與旨在緩解症狀的傳統藥物不同，生物製劑可針對特定的發炎通路，從而提高療效並實現長期緩解，尤其是在發炎性腸道疾病（IBD）患者中。此外，生物相似藥和下一代口服療法的開發有望提高藥物的可負擔性和市場滲透率。

2024年6月，美國FDA批准了SKYRIZI（risankizumab-rzaa）用於治療中度至重度活動性潰瘍性結腸炎，這標誌著生物製劑的應用勢頭日益強勁。

市場趨勢

影響市場的一個顯著趨勢是，人們越來越重視早期篩檢和預防性診斷。醫療保健系統正致力於透過分子診斷、生物標記檢測和基於人工智慧的內視鏡成像技術，早期發現胃腸道癌症和慢性疾病。這些進步正在改善患者的治療效果，同時也推動了對綜合治療和診斷解決方案的需求。

市場挑戰

限制市場擴張的主要挑戰是常用胃腸道藥物相關的不良反應風險和長期安全性問題。例如，長期使用質子幫浦抑制劑 (PPI) 與腎臟疾病、營養不良、骨折和感染有關。 監管警告和謹慎的處方實踐正在抑制某些傳統藥物細分市場的成長。

細分市場分析

依產品類型劃分，小分子藥物和傳統藥物將主導市場，在2026年佔71.36%的市場佔有率，這主要得益於其價格實惠和廣泛的可及性。

依治療方法劃分，抑酸療法將在2026年佔市場主導地位，市佔率為23.84%，主要得益於胃食道逆流（GERD）的高發生率和非處方藥（OTC）的強勁需求。

依給藥途徑劃分，口服給藥途徑將主導市場，在2026年佔70.41%的市場佔有率，這主要得益於其便利性和較高的患者依從性。

依應用領域劃分，發炎性腸道疾病（IBD）將佔最大市場佔有率，這主要得益於其高昂的治療費用和患者意識的提高。

依分銷管道劃分，零售藥局和藥局將引領市場，到 2025 年將佔 50.9% 的市場佔有率。

區域展望

北美將引領市場，2025 年市場規模將達到 358 億美元，2026 年將達到 376.9 億美元，主要得益於積極的研發活動和較高的疾病負擔。

預計到 2025 年，歐洲市場規模將達到 218.1 億美元，而亞太地區市場規模預計將達到 209.5 億美元，這主要得益於中國和印度醫療基礎設施的改善。

拉丁美洲和中東及非洲的成長速度將放緩，預計到 2025 年，市場規模將分別達到 34.4 億美元和 12.6 億美元。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 概述：胃腸道治療領域的技術進步
  • 主要國家的監管狀況
  • 主要產業趨勢：併購（併購）、業務合作等
  • 新產品發布：依主要公司劃分

第五章 全球胃腸道治療市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品類型劃分
    • 小分子藥物/傳統藥物
    • 生物製劑/生物相似藥
  • 市場分析、洞察與預測：依療法劃分
    • 抑酸療法
      • 質子幫浦抑制劑 (PPI)
      • 其他
    • 標靶療法
      • 抗體
      • JAK抑制劑
      • 其他
    • 抗發炎藥物和免疫調節劑
    • 抗生素
    • 止吐藥
    • 促動力藥和促分泌藥
    • 其他
  • 市場分析、洞察與預測：依給藥途徑
    • 口服
    • 腸外給藥
    • 其他
  • 市場分析、洞察與預測：依年齡組
    • 兒科
    • 成人
  • 市場分析、洞察與預測：依應用
    • 胃食道逆流症 (GERD)
    • 功能性胃腸疾病 (FGIDs)
    • 腸躁症 (IBS)
    • 發炎性腸道疾病 (IBD)
    • 胃腸道疾病癌症
    • 其他
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 零售藥局和藥局
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美胃腸道治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章 歐洲胃腸道治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪的納維亞
    • 歐洲其他地區

第八章 亞太地區胃腸道治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 日本
    • 中國
    • 印度
    • 澳大利亞
    • 東南亞
    • 亞太其他地區

第九章 拉丁美洲胃腸道治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲胃腸道治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會 (GCC) 國家
    • 南非
    • 中東和非洲其他地區

第十一章 競爭分析

  • 全球市佔率分析（2026）
  • 公司簡介
  • Johnson &Johnson
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Pfizer Inc.
  • Abbott
  • UCB S.A.
  • Bausch Health Companies Inc.
  • CELLTRION INC.
Product Code: FBI114337

Growth Factors of gastrointestinal (GI) therapeutics Market

The global gastrointestinal (GI) therapeutics market is witnessing consistent growth, driven by the rising prevalence of digestive disorders, increasing awareness, and continuous innovation in drug development. Gastrointestinal therapeutics include medications for conditions such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), GI cancers, and other functional GI disorders. According to Fortune Business Insights, the global gastrointestinal therapeutics market was valued at USD 80.60 billion in 2025, highlighting the significant demand for effective digestive health treatments worldwide.

Market Size and Forecast

In 2026, the global market is projected to grow to USD 89.11 billion, supported by increasing diagnosis rates, strong demand for acid suppression therapies, and expanding use of biologics for chronic GI conditions. Over the long term, the market is expected to reach USD 140.98 billion by 2034, registering a CAGR of 5.09% during the forecast period.

North America dominated the global gastrointestinal therapeutics market in 2025, accounting for a 42.32% market share, owing to high disease prevalence, strong healthcare infrastructure, and early adoption of advanced therapies.

Market Drivers

One of the key drivers fueling market growth is the increasing prevalence of gastrointestinal diseases globally. Lifestyle changes such as unhealthy diets, sedentary behavior, rising alcohol consumption, and stress have significantly contributed to the growing burden of GI disorders. This expanding patient population has increased demand for effective therapeutic solutions and advanced diagnostic procedures.

According to the Crohn's & Colitis Foundation, between 1.6 and 3.1 million people in the U.S. were living with inflammatory bowel disease as of June 2023, underscoring the need for long-term disease management and driving pharmaceutical innovation.

Market Restraints

Despite steady growth, the market faces restraints due to the high cost of advanced therapies, particularly biologics and targeted treatments. These therapies require extensive R&D investment, making them expensive and less accessible, especially in low- and middle-income countries. Limited insurance coverage further increases the financial burden on patients.

For example, the bundled cost of a 5 mg/kg dose of infliximab was reported at approximately USD 2,634 in the U.S., limiting affordability and slowing adoption of advanced therapies.

Market Opportunities

The rising focus on biologics and targeted therapies presents significant growth opportunities. Unlike conventional drugs that offer symptomatic relief, biologics target specific inflammatory pathways, providing improved efficacy and long-term remission, particularly in IBD patients. Additionally, the development of biosimilars and next-generation oral therapies is expected to improve affordability and market penetration.

In June 2024, the U.S. FDA approved SKYRIZI (risankizumab-rzaa) for moderately to severely active ulcerative colitis, reflecting the growing momentum in biologic drug adoption.

Market Trends

A prominent trend shaping the market is the increased emphasis on early screening and preventive diagnostics. Healthcare systems are focusing on early detection of GI cancers and chronic conditions through molecular diagnostics, biomarker testing, and AI-enabled endoscopic imaging. These advancements improve patient outcomes while supporting demand for integrated therapeutic and diagnostic solutions.

Market Challenges

A major challenge limiting market expansion is the risk of adverse drug reactions and long-term safety concerns associated with commonly used GI medications. For instance, prolonged use of proton pump inhibitors (PPIs) has been linked to kidney disease, nutrient deficiencies, bone fractures, and infections. Regulatory warnings and cautious prescribing practices have moderated growth in certain traditional drug segments.

Segmentation Analysis

By product type, small molecules and conventional drugs dominated the market, holding a 71.36% share in 2026, driven by affordability and widespread availability.

By therapy type, acid suppression therapies led the market with a 23.84% share in 2026, supported by high GERD prevalence and strong OTC demand.

By route of administration, the oral segment dominated with a 70.41% share in 2026, due to convenience and high patient adherence.

By application, inflammatory bowel disease (IBD) accounted for the largest share, driven by high treatment costs and rising patient awareness.

By distribution channel, retail pharmacies and drug stores led the market, holding 50.9% share in 2025.

Regional Outlook

North America led the market with USD 35.80 billion in 2025 and USD 37.69 billion in 2026, driven by strong R&D activity and high disease burden.

Europe reached USD 21.81 billion in 2025, while Asia Pacific recorded USD 20.95 billion in 2025, supported by improving healthcare infrastructure in China and India.

Latin America and Middle East & Africa showed moderate growth, with valuations of USD 3.44 billion and USD 1.26 billion respectively in 2025.

Competitive Landscape

The global market is semi-consolidated, with key players such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Pfizer Inc., and Bristol Myers Squibb leading due to diversified portfolios, strong pipelines, and global distribution networks. Continuous product approvals and biologic innovation support their dominance.

Conclusion

The global gastrointestinal therapeutics market is set to grow steadily from USD 80.60 billion in 2025 to USD 140.98 billion by 2034, driven by rising prevalence of GI disorders, expanding use of biologics, and growing focus on early diagnosis and preventive care. Although high treatment costs and safety concerns pose challenges, continuous R&D investments, targeted therapies, and biosimilar development are expected to enhance treatment accessibility and long-term disease management. Overall, the market will continue to evolve as a critical component of global healthcare, addressing the increasing burden of digestive diseases worldwide.

Segmentation By Product Type

  • Small Molecules/Conventional Drugs
  • Biologics & Biosimilars

By Therapy Type

Acid Suppression Therapies

  • Proton Pump Inhibitor (PPI)
  • Others
  • Targeted Therapies
  • Antibodies
  • JAK Inhibitors
  • Others
  • Anti-Inflammatory & Immunomodulators
  • Antibiotics
  • Antiemetics
  • Motility Agents & Secretagogues
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Others

By Age Group

  • Pediatrics
  • Adults

By Application

  • Gastroesophageal Reflux Disease (GERD)
  • Functional Gastrointestinal Disorders (FGIDs)
  • Inflammatory Bowel Disease (IBD)
  • Irritable Bowel Syndrome (IBS)
  • GI Cancers
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies

By Region

North America (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country)

  • U.S.
  • Canada

Europe (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)

  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe

Asia Pacific (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)

  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific

Latin America (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa (By Product Type, Therapy Type, Route of Administration, Age Group, Application, Distribution Channel, and Country/Sub-region)

  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Overview: Technological Advancements in Gastrointestinal Therapeutics
  • 4.2. Regulatory Scenario, By Key Countries/Regions
  • 4.3. Key Industry Developments (Mergers, Acquisitions, and Collaborations etc.)
  • 4.4. New Product Launches, By Key Players

5. Global Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 5.1.1. Small Molecules/Conventional Drugs
    • 5.1.2. Biologics & Biosimilars
  • 5.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 5.2.1. Acid Suppression Therapies
      • 5.2.1.1. Proton Pump Inhibitor (PPI)
      • 5.2.1.2. Others
    • 5.2.2. Targeted Therapies
      • 5.2.2.1. Antibodies
      • 5.2.2.2. JAK Inhibitors
      • 5.2.2.3. Others
    • 5.2.3. Anti-Inflammatory & Immunomodulators
    • 5.2.4. Antibiotics
    • 5.2.5. Antiemetics
    • 5.2.6. Motility Agents & Secretagogues
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.3.1. Oral
    • 5.3.2. Parenteral
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Age Group
    • 5.4.1. Pediatrics
    • 5.4.2. Adults
  • 5.5. Market Analysis, Insights and Forecast - By Application
    • 5.5.1. Gastroesophageal Reflux Disease (GERD)
    • 5.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 5.5.3. Irritable Bowel Syndrome (IBS)
    • 5.5.4. Inflammatory Bowel Disease (IBD)
    • 5.5.5. GI Cancers
    • 5.5.6. Others
  • 5.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.6.1. Hospital Pharmacies
    • 5.6.2. Retail Pharmacies & Drug Stores
    • 5.6.3. Online Pharmacies
  • 5.7. Market Analysis, Insights and Forecast - By Region
    • 5.7.1. North America
    • 5.7.2. Europe
    • 5.7.3. Asia Pacific
    • 5.7.4. Latin America
    • 5.7.5. Middle East & Africa

6. North America Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 6.1.1. Small Molecules/Conventional Drugs
    • 6.1.2. Biologics & Biosimilars
  • 6.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 6.2.1. Acid Suppression Therapies
      • 6.2.1.1. Proton Pump Inhibitor (PPI)
      • 6.2.1.2. Others
    • 6.2.2. Targeted Therapies
      • 6.2.2.1. Antibodies
      • 6.2.2.2. JAK Inhibitors
      • 6.2.2.3. Others
    • 6.2.3. Anti-Inflammatory & Immunomodulators
    • 6.2.4. Antibiotics
    • 6.2.5. Antiemetics
    • 6.2.6. Motility Agents & Secretagogues
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.3.1. Oral
    • 6.3.2. Parenteral
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Age Group
    • 6.4.1. Pediatrics
    • 6.4.2. Adults
  • 6.5. Market Analysis, Insights and Forecast - By Application
    • 6.5.1. Gastroesophageal Reflux Disease (GERD)
    • 6.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 6.5.3. Irritable Bowel Syndrome (IBS)
    • 6.5.4. Inflammatory Bowel Disease (IBD)
    • 6.5.5. GI Cancers
    • 6.5.6. Others
  • 6.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.6.1. Hospital Pharmacies
    • 6.6.2. Retail Pharmacies & Drug Stores
    • 6.6.3. Online Pharmacies
  • 6.7. Market Analysis, Insights and Forecast - By Country
    • 6.7.1. U.S.
    • 6.7.2. Canada

7. Europe Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 7.1.1. Small Molecules/Conventional Drugs
    • 7.1.2. Biologics & Biosimilars
  • 7.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 7.2.1. Acid Suppression Therapies
      • 7.2.1.1. Proton Pump Inhibitor (PPI)
      • 7.2.1.2. Others
    • 7.2.2. Targeted Therapies
      • 7.2.2.1. Antibodies
      • 7.2.2.2. JAK Inhibitors
      • 7.2.2.3. Others
    • 7.2.3. Anti-Inflammatory & Immunomodulators
    • 7.2.4. Antibiotics
    • 7.2.5. Antiemetics
    • 7.2.6. Motility Agents & Secretagogues
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.3.1. Oral
    • 7.3.2. Parenteral
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Age Group
    • 7.4.1. Pediatrics
    • 7.4.2. Adults
  • 7.5. Market Analysis, Insights and Forecast - By Application
    • 7.5.1. Gastroesophageal Reflux Disease (GERD)
    • 7.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 7.5.3. Irritable Bowel Syndrome (IBS)
    • 7.5.4. Inflammatory Bowel Disease (IBD)
    • 7.5.5. GI Cancers
    • 7.5.6. Others
  • 7.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.6.1. Hospital Pharmacies
    • 7.6.2. Retail Pharmacies & Drug Stores
    • 7.6.3. Online Pharmacies
  • 7.7. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 7.7.1. U.K.
    • 7.7.2. Germany
    • 7.7.3. France
    • 7.7.4. Spain
    • 7.7.5. Italy
    • 7.7.6. Scandinavia
    • 7.7.7. Rest of Europe

8. Asia Pacific Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 8.1.1. Small Molecules/Conventional Drugs
    • 8.1.2. Biologics & Biosimilars
  • 8.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 8.2.1. Acid Suppression Therapies
      • 8.2.1.1. Proton Pump Inhibitor (PPI)
      • 8.2.1.2. Others
    • 8.2.2. Targeted Therapies
      • 8.2.2.1. Antibodies
      • 8.2.2.2. JAK Inhibitors
      • 8.2.2.3. Others
    • 8.2.3. Anti-Inflammatory & Immunomodulators
    • 8.2.4. Antibiotics
    • 8.2.5. Antiemetics
    • 8.2.6. Motility Agents & Secretagogues
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.3.1. Oral
    • 8.3.2. Parenteral
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Age Group
    • 8.4.1. Pediatrics
    • 8.4.2. Adults
  • 8.5. Market Analysis, Insights and Forecast - By Application
    • 8.5.1. Gastroesophageal Reflux Disease (GERD)
    • 8.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 8.5.3. Irritable Bowel Syndrome (IBS)
    • 8.5.4. Inflammatory Bowel Disease (IBD)
    • 8.5.5. GI Cancers
    • 8.5.6. Others
  • 8.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.6.1. Hospital Pharmacies
    • 8.6.2. Retail Pharmacies & Drug Stores
    • 8.6.3. Online Pharmacies
  • 8.7. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 8.7.1. Japan
    • 8.7.2. China
    • 8.7.3. India
    • 8.7.4. Australia
    • 8.7.5. Southeast Asia
    • 8.7.6. Rest of Asia Pacific

9. Latin America Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 9.1.1. Small Molecules/Conventional Drugs
    • 9.1.2. Biologics & Biosimilars
  • 9.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 9.2.1. Acid Suppression Therapies
      • 9.2.1.1. Proton Pump Inhibitor (PPI)
      • 9.2.1.2. Others
    • 9.2.2. Targeted Therapies
      • 9.2.2.1. Antibodies
      • 9.2.2.2. JAK Inhibitors
      • 9.2.2.3. Others
    • 9.2.3. Anti-Inflammatory & Immunomodulators
    • 9.2.4. Antibiotics
    • 9.2.5. Antiemetics
    • 9.2.6. Motility Agents & Secretagogues
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.3.1. Oral
    • 9.3.2. Parenteral
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Age Group
    • 9.4.1. Pediatrics
    • 9.4.2. Adults
  • 9.5. Market Analysis, Insights and Forecast - By Application
    • 9.5.1. Gastroesophageal Reflux Disease (GERD)
    • 9.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 9.5.3. Irritable Bowel Syndrome (IBS)
    • 9.5.4. Inflammatory Bowel Disease (IBD)
    • 9.5.5. GI Cancers
    • 9.5.6. Others
  • 9.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.6.1. Hospital Pharmacies
    • 9.6.2. Retail Pharmacies & Drug Stores
    • 9.6.3. Online Pharmacies
  • 9.7. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.7.1. Brazil
    • 9.7.2. Mexico
    • 9.7.3. Rest of Latin America

10. Middle East & Africa Gastrointestinal Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type Type
    • 10.1.1. Small Molecules/Conventional Drugs
    • 10.1.2. Biologics & Biosimilars
  • 10.2. Market Analysis, Insights and Forecast - By Therapy Type
    • 10.2.1. Acid Suppression Therapies
      • 10.2.1.1. Proton Pump Inhibitor (PPI)
      • 10.2.1.2. Others
    • 10.2.2. Targeted Therapies
      • 10.2.2.1. Antibodies
      • 10.2.2.2. JAK Inhibitors
      • 10.2.2.3. Others
    • 10.2.3. Anti-Inflammatory & Immunomodulators
    • 10.2.4. Antibiotics
    • 10.2.5. Antiemetics
    • 10.2.6. Motility Agents & Secretagogues
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.3.1. Oral
    • 10.3.2. Parenteral
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Age Group
    • 10.4.1. Pediatrics
    • 10.4.2. Adults
  • 10.5. Market Analysis, Insights and Forecast - By Application
    • 10.5.1. Gastroesophageal Reflux Disease (GERD)
    • 10.5.2. Functional Gastrointestinal Disorders (FGIDs)
    • 10.5.3. Irritable Bowel Syndrome (IBS)
    • 10.5.4. Inflammatory Bowel Disease (IBD)
    • 10.5.5. GI Cancers
    • 10.5.6. Others
  • 10.6. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.6.1. Hospital Pharmacies
    • 10.6.2. Retail Pharmacies & Drug Stores
    • 10.6.3. Online Pharmacies
  • 10.7. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.7.1. GCC
    • 10.7.2. South Africa
    • 10.7.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2026)
  • 11.2. Company Profiles (Overview, Products, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Johnson & Johnson
    • 11.2.2. AbbVie Inc.
    • 11.2.3. Takeda Pharmaceutical Company Limited
    • 11.2.4. Bristol-Myers Squibb Company
    • 11.2.5. Bayer AG
    • 11.2.6. Pfizer Inc.
    • 11.2.7. Abbott
    • 11.2.8. UCB S.A.
    • 11.2.9. Bausch Health Companies Inc.
    • 11.2.10. CELLTRION INC.

List of Tables

  • Table 1: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 2: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 3: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 4: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 5: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 6: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 7: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 8: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 9: Global Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Region, 2021-2034
  • Table 10: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 11: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 12: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 13: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 14: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 15: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 16: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 17: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 18: North America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country, 2021-2034
  • Table 19: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 20: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 21: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 22: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 23: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 24: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 25: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 26: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 27: Europe Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 28: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 29: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 30: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 31: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 32: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 33: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 34: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 35: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 36: Asia Pacific Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 37: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 38: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 39: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 40: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 41: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 42: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 43: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 44: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 45: Latin America Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 46: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Product Type, 2021-2034
  • Table 47: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Acid Suppression Therapies, 2021-2034
  • Table 48: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Targeted Therapies, 2021-2034
  • Table 49: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Therapy Type, 2021-2034
  • Table 50: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Route of Administration, 2021-2034
  • Table 51: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Age Group, 2021-2034
  • Table 52: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Application, 2021-2034
  • Table 53: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Distribution Channel, 2021-2034
  • Table 54: Middle East & Africa Gastrointestinal Therapeutics Market Revenue (USD Billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Gastrointestinal Therapeutics Market Revenue Breakdown (USD Billion, %) By Region, 2026 & 2034
  • Figure 2: Global Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026 & 2034
  • Figure 3: Global Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026 & 2034
  • Figure 4: Global Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026 & 2034
  • Figure 5: Global Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026 & 2034
  • Figure 6: Global Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026 & 2034
  • Figure 7: Global Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026 & 2034
  • Figure 8: Global Gastrointestinal Therapeutics Market Value (USD Billion), By Region, 2026 & 2034
  • Figure 9: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
  • Figure 10: North America Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
  • Figure 11: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
  • Figure 12: North America Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
  • Figure 13: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
  • Figure 14: North America Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
  • Figure 15: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
  • Figure 16: North America Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
  • Figure 17: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
  • Figure 18: North America Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
  • Figure 19: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
  • Figure 20: North America Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
  • Figure 21: North America Gastrointestinal Therapeutics Market Value (USD Billion), By Country, 2026 & 2034
  • Figure 22: North America Gastrointestinal Therapeutics Market Value Share (%), By Country, 2026
  • Figure 23: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
  • Figure 24: Europe Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
  • Figure 25: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
  • Figure 26: Europe Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
  • Figure 27: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
  • Figure 28: Europe Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
  • Figure 29: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
  • Figure 30: Europe Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
  • Figure 31: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
  • Figure 32: Europe Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
  • Figure 33: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
  • Figure 34: Europe Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
  • Figure 35: Europe Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 36: Europe Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 37: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
  • Figure 38: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
  • Figure 39: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
  • Figure 40: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
  • Figure 41: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
  • Figure 42: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
  • Figure 43: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
  • Figure 44: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
  • Figure 45: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
  • Figure 46: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
  • Figure 47: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
  • Figure 48: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
  • Figure 49: Asia Pacific Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 50: Asia Pacific Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 51: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
  • Figure 52: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
  • Figure 53: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
  • Figure 54: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
  • Figure 55: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
  • Figure 56: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
  • Figure 57: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
  • Figure 58: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
  • Figure 59: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
  • Figure 60: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
  • Figure 61: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
  • Figure 62: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
  • Figure 63: Latin America Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 64: Latin America Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 65: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Product Type, 2026 & 2034
  • Figure 66: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Product Type, 2026
  • Figure 67: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Therapy Type, 2026 & 2034
  • Figure 68: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Therapy Type, 2026
  • Figure 69: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Route of Administration, 2026 & 2034
  • Figure 70: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Route of Administration, 2026
  • Figure 71: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Age Group, 2026 & 2034
  • Figure 72: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Age Group, 2026
  • Figure 73: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Application, 2026 & 2034
  • Figure 74: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Application, 2026
  • Figure 75: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Distribution Channel, 2026 & 2034
  • Figure 76: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Distribution Channel, 2026
  • Figure 77: Middle East & Africa Gastrointestinal Therapeutics Market Value (USD Billion), By Country/ Sub-region, 2026 & 2034
  • Figure 78: Middle East & Africa Gastrointestinal Therapeutics Market Value Share (%), By Country/ Sub-region, 2026
  • Figure 79: Global Gastrointestinal Therapeutics Market Share (%), By Company, 2026